Research Progress of Albumin-bound Paclitaxel in Gynecologic Oncology
ZENG Jing
ZHANG Rong
Abstract：Albumin-bound paclitaxel is a novel formulation of paclitaxel with albumin as its solvent. Compare to the conventional paclitaxel formulation (solvent is polyoxyethylene castor oil and ethanol),its anti-tumor capability is more effective and hematologic toxicity ,severe allergic reaction and other side effects are less. In recent years ,albumin-bound paclitaxel are widely used on clinical studies of gynecologic oncology. There are three Phase Ⅱ clinical studies currently reported on ovarian cancer,nanoparticle albumin-bound paclitaxel in platinum-sensitive patients and platinum-resistant patients with ovarian,peritoneal,or fallopian tube canceral and bevacizumab with albumin-bound paclitaxel in patients with recurrent,platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma,which have shown the efficacy and tolerated adverse reactions. The study reported a phase Ⅱ trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer and point out that albumin-bound paclitaxel is a considering drug with little side effects. In short ,there is only a few study on albumin-bound paclitaxel in gynecologic oncology until now and we need more further study.
Keywords：PaclitaxelUterine cervical neoplasmsOvarian neoplasmsUterine neoplasmsCarcinomaSarcoma
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 232-235 )